Superconductor Technologies, Inc. (SCON), Pfizer Inc. (PFE), ACADIA Pharmaceuticals Inc. (ACAD): Sabby Capital’s Latest Moves in Healthcare Sector

Page 2 of 2

A total of 23 hedge funds had investments worth $1.13 billion in  ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) at the end of 2014, as compared to 22 firms with $912.48 million a quarter earlier. Andreas Halvorsen’s Viking Global held 2.96 million shares valued at $93.86 million.

Sabby Capital initiated a stake in Merck & Co., Inc. (NYSE:MRK) during the fourth quarter and disclosed 211,100 shares valued at $11.99 million in its latest 13F filing. The $167.14 billion company acquired the specialty antibiotic company, Cubist Pharmaceuticals for $9.5 billion in December last year. Just yesterday, Merck & Co., Inc. (NYSE:MRK) announced that it was increasing its share repurchase program by $10 billion to $11.7 billion. The stock has appreciated by about 5.5% over the last year. Another shareholder in the company is Cliff Asness’ AQR Capital Management with about 7.48 million shares valued at $425.07 million.

Disclosure: none

Page 2 of 2